[go: up one dir, main page]

UY35900A - NEW DOSAGE AND FORMULATION - Google Patents

NEW DOSAGE AND FORMULATION

Info

Publication number
UY35900A
UY35900A UY0001035900A UY35900A UY35900A UY 35900 A UY35900 A UY 35900A UY 0001035900 A UY0001035900 A UY 0001035900A UY 35900 A UY35900 A UY 35900A UY 35900 A UY35900 A UY 35900A
Authority
UY
Uruguay
Prior art keywords
formulation
new dosage
micrograms
salmeterol
pharmaceutically acceptable
Prior art date
Application number
UY0001035900A
Other languages
Spanish (es)
Inventor
Arlt Matthias
Ivanoff Nathalie Blandine
Vives Blazquez Montserrat
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY35900A publication Critical patent/UY35900A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una composición farmacéutica en polvo seco para inhalación, que comprende salmeterol o una sal farmacéuticamente aceptable del mismo y propionato de fluticasona en mezcla con un vehículo en polvo seco farmacéuticamente aceptable, que proporciona una dosis medida de salmeterol / propionato de fluticasona equivalente a aproximadamente 16/280 microgramos o a 16/140 microgramos.The invention provides a dry powder pharmaceutical composition for inhalation, comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate in admixture with a pharmaceutically acceptable dry powder carrier, which provides a measured dose of fluticasone salmeterol / propionate equivalent to approximately 16/280 micrograms or 16/140 micrograms.

UY0001035900A 2013-12-19 2014-12-19 NEW DOSAGE AND FORMULATION UY35900A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382533 2013-12-19

Publications (1)

Publication Number Publication Date
UY35900A true UY35900A (en) 2015-07-31

Family

ID=49886823

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001035901A UY35901A (en) 2013-12-19 2014-12-19 NEW DOSAGE AND FORMULATION
UY0001035900A UY35900A (en) 2013-12-19 2014-12-19 NEW DOSAGE AND FORMULATION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001035901A UY35901A (en) 2013-12-19 2014-12-19 NEW DOSAGE AND FORMULATION

Country Status (4)

Country Link
AR (2) AR098867A1 (en)
TW (2) TW201605432A (en)
UY (2) UY35901A (en)
WO (2) WO2015091287A1 (en)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (en) 1979-02-05 1980-08-05 Chiesi Paolo Inhaler for powdered medicinal substances, with combined dosing function
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (en) 1984-10-04 1986-09-12 Orion Yhtymae Oy DOSERINGSANORDNING
DE3927170A1 (en) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg INHALATOR
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (en) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg GAS-FREE INHALATION DEVICE
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (en) 1992-11-24 1994-05-26 Bayer Ag Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion
EP0674533B1 (en) 1992-12-18 1999-03-10 Schering Corporation Inhaler for powdered medications
WO1997000703A1 (en) 1995-06-21 1997-01-09 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
ITMI20010357U1 (en) 2001-06-28 2002-12-30 Plastiape Spa INHALER DEVICE
US8962601B2 (en) * 2002-08-29 2015-02-24 Cipla Ltd Pharmaceutical products and composition comprising specific anticholinergic agents, β-2 agonists and corticosteroids
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
PL1616592T3 (en) 2004-07-16 2011-03-31 Astrazeneca Ab Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge for use with this inhaler
TR201000681A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations inhaled.
WO2011145109A1 (en) * 2010-05-20 2011-11-24 Sun Pharma Advanced Research Company Ltd., Dry powder inhalation composition

Also Published As

Publication number Publication date
WO2015091285A1 (en) 2015-06-25
WO2015091287A1 (en) 2015-06-25
TW201605432A (en) 2016-02-16
TW201609201A (en) 2016-03-16
UY35901A (en) 2015-07-31
AR098867A1 (en) 2016-06-22
AR098868A1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
DOP2016000175A (en) (2S) -N - [(1S) -1-CIANO-2-FENILETIL] -1,4-OXAZEPAN-2-CARBOXAMIDS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE 1
CL2015002733A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
HUE039827T2 (en) Dry powder formulation containing anticholinergic, corticosteroid and beta-adrenergic substances for administration by inhalation
CL2013003497A1 (en) Combination pharmaceutical product in the form of dry powder for administration by means of an inhaler comprising a umeclidinium salt of a defined group and 100 mcg / dose of fluticasone furoate, without other additional assets; use for the treatment of inflammatory or respiratory diseases.
BR112015027017A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
DOP2014000269A (en) NEW DOSAGE AND FORMULATION
DOP2015000005A (en) DERIVATIVES OF ESTRA 1,3,5 (10), 16 TETRAENE 3 SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
TR201008226A2 (en) An inhalation device containing capsules.
MX2022009231A (en) DRY POWDER INHALER AND METHOD OF USE.
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
AR100368A1 (en) TREATMENT OF RESPIRATORY DISORDERS
BR112018006206A2 (en) composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination
CL2016001843A1 (en) Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal.
CL2015002702A1 (en) Micronized pharmaceutical compositions.
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
MX2017013634A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO DRUGS FROM PARTICLES AND A POWDER.
MX2017013633A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES.
UY35900A (en) NEW DOSAGE AND FORMULATION
TR200907913A2 (en) Pharmaceutical composition in dry powder form for inhalation
NI201400138A (en) NEW DOSAGE AND FORMULATION.
MX2019001701A (en) FIXED DOSE PHARMACEUTICAL COMPOSITION INCLUDING MOMETASONE AND AZELASTINE.
TR201716155A1 (en) Pharmaceutical formulation containing a corticosteroid in combination with a beta-2 agonist.
TR201716207A2 (en) Pharmaceutical formulations containing vilanterol and umeclidinium.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230